4767-41-3

Usage

Explanation

The full chemical name of the compound, indicating its structure and functional groups.

Explanation

The compound is derived from hydrazine, a basic chemical structure.
3. Monohydrochloride Salt

Explanation

The compound is a salt formed by the reaction of hydrochloric acid with the amine group of the compound.

Explanation

The compound contains hydrazine, a 4-methoxyphenylmethyl group, and a monohydrochloride group.
5. 4-Methoxyphenylmethyl Group

Explanation

The presence of a methoxy (CH3O) group attached to a phenylmethyl (C6H5CH2) group.

Explanation

The compound is commonly used in research and pharmaceutical applications.

Explanation

The compound's properties and structure make it a promising candidate for further research and development in these fields.

Explanation

The compound's structure is characterized by an imidamide core, a 4-methoxyphenylmethyl substituent, and a monohydrochloride salt form.

Explanation

The compound is soluble in water and may also be soluble in certain organic solvents, depending on its specific properties.

Explanation

The compound may degrade or react under certain conditions, such as exposure to light, heat, or moisture, which could affect its stability and reactivity.

Derivative of

Hydrazine

Functional Groups

Hydrazine, 4-methoxyphenylmethyl, and monohydrochloride

Applications

Research and pharmaceutical

Potential Applications

Medicinal chemistry and pharmaceutical synthesis

Structure

Imidamide derivative with a 4-methoxyphenylmethyl substituent and a monohydrochloride salt form

Solubility

Soluble in water and some organic solvents

Stability

May be sensitive to light, heat, and moisture

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 127099-85-8 N-Cyanoguanidine 
• 17061-61-9 4-methoxybenzylamine hydrochloride 

Downstream Products

• 1194506-55-2 1-(4-methoxy-benzyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride 
• 1333500-44-9 C₁₆H₂₃N₅O*ClH 
• 1333500-40-5 7,9-diamino-10-(4'-methoxybenzyl)-6,8,10-triazaspiro[4.5]deca-6,8-diene hydrochloride 
• 1333500-36-9 4,6-diamino-2-ethyl-2-methyl-1,2-dihydro-1-(4'-methoxybenzyl)-1,3,5-triazine hydrochloride 

Relevant academic research and scientific papers

Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2

Membrane transporters play a significant role in the transport of many endogenous and exogenous compounds. The knowledge of transporter substrate requirements has allowed further development of drugs that utilize them to ensure tissue permeation. In this

BIGUANIDE COMPOUND AND USE THEREOF

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Synthesis and antimicrobial activity of N1-benzyl or N 1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamines

The emergence and spread of multidrug-resistant strains of Staphylococcus aureus and Mycobacterium tuberculosis are generating a threat to public health worldwide. In the current study, a series of N1-benzyl and N 1-benzyloxy-1,6-dihydro-1,3,5-triazine-2,4-diamine derivatives were synthesized and investigated for their antimicrobial activity against S. aureus, and Mycobacterium smegmatis which is taxonomically related to M. tuberculosis. Most of the compounds exhibited good activity against M. smegmatis as determined by comparison of diameters of the zone of inhibition of test compounds and standard antibiotics. Compound 7o showed potent antimycobacterial activity against M. smegmatis without mammalian DHFR inhibition liability. The results from this study indicate that 1-benzyl derivatives of 1,6-dihydro-1,3,5- triazine-2,4-diamines may be used as lead compounds for the discovery of antimycobacterial agents.

Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers

Neuronal sodium channels blockers interfere with ion flux and have been used for managing neuropathic pain, epilepsy, and cerebral ischemic disorders. In the current study, four groups of 2,4-diamino-1,3,5-triazine derivatives were synthesized and investigated for their neuronal sodium channels binding activity. 5-Aryl-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamines (4a-4j) were found to have the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a-4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.